Core Points - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [2][3] - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its new drug application [3] - Investors who suffered losses during the relevant period have until October 14, 2025, to request to be appointed as lead plaintiff [4] Company Details - Unicycive Therapeutics, Inc. is currently facing legal challenges due to claims of misleading public statements regarding its compliance and regulatory status [3] - The firm Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]

Group 1 - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Unicycive [4][9]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's ability to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [7]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock fell by $2.03 per share, or 29.85%, closing at $4.77 [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [1][3]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is under scrutiny for overstating its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA [3]. - The company’s stock experienced significant declines following negative FDA communications regarding manufacturing compliance issues [4][5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Unicycive, with the firm encouraging affected investors to discuss their legal rights [1][6]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members [6]. Group 3: Stock Performance - On June 10, 2025, Unicycive's stock fell by $3.68 per share (40.89%) to close at $5.32 after the company disclosed FDA compliance deficiencies [4]. - Following a Complete Response Letter from the FDA on June 30, 2025, the stock dropped by $2.03 per share (29.85%) to close at $4.77 [5].

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly misleading investors regarding the readiness of its drug application and compliance with FDA manufacturing requirements [1][2]. Group 1: Allegations and Company Background - Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing therapies for unmet medical needs in the U.S. [1] - The lawsuit claims that Unicycive misrepresented the prospects of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) intended for treating hyperphosphatemia in chronic kidney disease patients on dialysis [2]. - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. Group 2: Recent Developments - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in current good manufacturing practice (cGMP) compliance at a third-party manufacturing vendor, which impacted discussions regarding the drug label [3]. - Following this announcement, Unicycive's stock price dropped over 40% [3]. - On June 30, 2025, the FDA issued a Complete Response Letter for the OLC NDA, further citing the cGMP deficiencies, leading to an additional stock price decline of nearly 30%, closing at $4.77 per share [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Unicycive and can contact Robbins LLP to serve as lead plaintiff before the October 14, 2025 deadline [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Firm Background - Robbins LLP is recognized for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2] - It is alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [2] - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3] - Class members may be entitled to compensation without incurring out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]

NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Unicycive Therapeutics, Inc. investors who were adversely affected by alleged securities fraud between March 29, 2024 and June 27, 2025. Follow the link below to get more information and be contacted by a member of our team:https: ...

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/unicycive-therapeutics-inc-loss-submission-form/?id=165015&from=3 CL ...

Core Viewpoint - Unicycive Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [2][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 29, 2024, to June 27, 2025 [2]. - Allegations include overstating Unicycive's readiness to meet FDA manufacturing compliance and the regulatory prospects of its oxylanthanum carbonate new drug application [2]. Group 2: Shareholder Actions - Shareholders who purchased UNCY shares during the class period are encouraged to register for the class action and can seek lead plaintiff status by the deadline of October 14, 2025 [3]. - Registration allows shareholders to receive updates through portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Unicycive [4][9]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [7]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock price fell by $2.03 per share, or 29.85%, closing at $4.77 [8].